From prohibited to prescribed: The rescheduling of MDMA and psilocybin in Australia

Abstract

Get full access to this article

View all access options for this article.

References

Chiruta

(2022) Freedom of Information: Psilocybin and MDMA Therapeutic Use Approvals. Available at: https://www.ifta.org.au/post/psilocybin-and-mdma-therapeutic-use-approvals.

Greif

Surkala

(2020) Compassionate use of psychedelics. Medicine, Health Care, and Philosophy 23(3): 485–496.

Gukasyan

Davis

Barrett

, et al. (2022) Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology 36(2): 151–158.

Mind Medicine Australia (MMA) (2020a) Application to Reschedule N,ɑ-DIMETHYL-3,4 (METHYLENEDIOXY)PHENYLETHYLAME (MDMA) from Schedule 9 to Schedule 8 of the Poison Standards. Available at: https://mindmedicineaustralia.org.au/wp-content/uploads/MMA-MDMA-Rescheduling-S9-to-S8-15-July-2020-FINAL.pdf.

Mind Medicine Australia (MMA) (2020b) Application to Reschedule Psilocybine1 from Schedule 9 to Schedule 8 of the Poison Standards. Available at: https://mindmedicineaustralia.org.au/wp-content/uploads/MINDME1.pdf.

National Drugs and Poisons Schedule Committee (NDPSC) (2009) Record of Reasons 57th Meeting 20–21 October, 2009. Available at: https://www.tga.gov.au/sites/default/files/ndpsc-record-57.pdf.

Therapeutic Goods Administration (TGA) (2022) FOI 4104 document 1. Available at: https://www.tga.gov.au/sites/default/files/2022-12/foi-4104-01_0.PDF.

Therapeutic Goods Administration (TGA) (2023) Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. Available at: https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists (accessed Feb 2023).